Theratechnologies Inc. (NASDAQ:THTX) Short Interest Update

Theratechnologies Inc. (NASDAQ:THTX - Get Free Report) saw a large growth in short interest in August. As of August 15th, there was short interest totaling 300,200 shares, a growth of 31.4% from the July 31st total of 228,400 shares. Based on an average daily trading volume, of 484,300 shares, the days-to-cover ratio is currently 0.6 days. Approximately 0.8% of the shares of the company are short sold. Approximately 0.8% of the shares of the company are short sold. Based on an average daily trading volume, of 484,300 shares, the days-to-cover ratio is currently 0.6 days.

Institutional Trading of Theratechnologies

Several hedge funds and other institutional investors have recently bought and sold shares of THTX. Raymond James Financial Inc. purchased a new stake in Theratechnologies during the 4th quarter valued at $27,000. Bank of America Corp DE raised its holdings in Theratechnologies by 1,416.7% during the 4th quarter. Bank of America Corp DE now owns 16,487 shares of the company's stock valued at $30,000 after buying an additional 15,400 shares during the period. BNP Paribas Financial Markets bought a new position in Theratechnologies in the 4th quarter valued at $36,000. Stonepine Capital Management LLC bought a new position in Theratechnologies in the 1st quarter valued at $36,000. Finally, Acadian Asset Management LLC bought a new position in Theratechnologies in the 1st quarter valued at $39,000.

Theratechnologies Price Performance

Shares of NASDAQ:THTX traded up $0.02 during mid-day trading on Friday, reaching $3.30. 696,400 shares of the company traded hands, compared to its average volume of 344,956. The company's 50 day moving average price is $3.20 and its 200-day moving average price is $2.57. The firm has a market cap of $151.73 million, a PE ratio of -17.37 and a beta of 0.51. Theratechnologies has a 52 week low of $1.12 and a 52 week high of $3.31.

Theratechnologies (NASDAQ:THTX - Get Free Report) last announced its quarterly earnings data on Wednesday, July 9th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.08). The company had revenue of $17.73 million during the quarter, compared to the consensus estimate of $24.30 million. On average, research analysts predict that Theratechnologies will post 0.01 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Jones Trading downgraded Theratechnologies from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 3rd. One investment analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy".

About Theratechnologies

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.